Intriguingly, in MS patients treated with Natalizumab, Th cells overcome α4 blockade by upregulating alternative adhesion receptors, such as PSGL-1 and melanoma CAM (MCAM) (Schneider-Hohendorf et al., 2014). This evidence concerns the gene SELPLG and myeloid sarcoma.